Review article: Cytochrome P450 from discovery to pandemic

Sonali Manwatkar

doi:10.53730/ijhs.v6nS1.6880

Authors

Sonali Manwatkar Vishwakarma University, School of Pharmacy, Pune, Maharashtra, INDIA

Keywords:

Cytochrome P450, Drug discovery, inflammation, cancer, COVID-19

Abstract

Discovery of the new drug or evaluation of chemical moiety which possesses drug like properties are need to be check for cytochrome P450 studies. Cytochrome P450 (CYP450) enzymes responsible and involved in variety of biochemical reaction. It plays vital role in detoxification of xenobiotics (Drugs, foreign particles, toxins etc) with the help of metabolism processes. It also has important function for the synthesis of various messengers or hormones. In vitro CYP450 studies responsible for the determination of pharmacokinetics parameters like half-life and clearance of drugs. Inhibition of CYP450 and induction of CYP450 undergoes drug-drug interaction. Concomitant medication can induce or inhibit the CYP450, resulting in drug adverse reaction. Interindividual efficacy of drug and disease susceptibility depends on the genetic polymorphism in CYP gene. During the drug discovery process, experiments designed set to check the metabolism of drug by various isoforms of CYPs like CYP1A2, 2B6, 2C9, 2C19, 2D6 and 3A4 associated metabolism. Novel COVID-19 disease progress due to multiplication of SARS-CoV-02 viruses in the human’s body and transmit to other person by contaminated droplets. Since it is novel disease, mortality rate high due to lack of evidenced based clinical studies.

Downloads

Download data is not yet available.

References

Bierle, D. M., Ganesh, R., Tulledge-Scheitel, S., Hanson, S. N., Arndt, L. L., Wilker, C. G., & Razonable, R. R. (2022). Monoclonal Antibody Treatment of Breakthrough COVID-19 in Fully Vaccinated Individuals with High-Risk Comorbidities. Journal of Infectious Diseases, 225(4), 598–602. https://doi.org/10.1093/infdis/jiab570

Biotransformation, F. A. (n.d.). Drug interactions due to cytochrome P450. 421–423.

Chung, T. D. Y., Terry, D. B., & Smith, L. H. (n.d.). In Vitro and In Vivo Assessment of ADME and PK Properties During Lead Selection and Lead Optimization-Guidelines, Benchmarks and Rules of Thumb Flow Chart of a Two-tier Approach for In Vitro and In Vivo Analysis. http://www.merckmanuals.com/professional/clinical-pharmacology/pharmacokinetics/overview-of-

Cruz-Teran, C., Tiruthani, K., McSweeney, M., Ma, A., Pickles, R., & Lai, S. K. (2021). Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy. Advanced Drug Delivery Reviews, 169, 100–117. https://doi.org/10.1016/j.addr.2020.12.004

CYP-cancer diabetes atherosclerosis.pdf. (n.d.).

Deb, S., & Arrighi, S. (2021a). Potential Effects of COVID-19 on Cytochrome P450-Mediated Drug Metabolism and Disposition in Infected Patients. European Journal of Drug Metabolism and Pharmacokinetics, 46(2), 185–203. https://doi.org/10.1007/s13318-020-00668-8

Deb, S., & Arrighi, S. (2021b). Potential Effects of COVID-19 on Cytochrome P450-Mediated Drug Metabolism and Disposition in Infected Patients. In European Journal of Drug Metabolism and Pharmacokinetics (Vol. 46, Issue 2, pp. 185–203). Adis. https://doi.org/10.1007/s13318-020-00668-8

Demopoulos, C., Antonopoulou, S., & Theoharides, T. C. (2020). COVID-19, microthromboses, inflammation, and platelet activating factor. In BioFactors (Vol. 46, Issue 6, pp. 927–933). Blackwell Publishing Inc. https://doi.org/10.1002/biof.1696

El-ghiaty, M. A., Shoieb, S. M., & El-kadi, A. O. S. (2020). Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19 . The COVID-19 resource centre is hosted on Elsevier Connect , the company ’ s public news and information . January.

Food and Drug Administration. (2017). In vitro Metabolism- and Transporter-Mediated Drug-Drug Interaction Studies Guidance for Industry. FDA Guidelines, 2017-10–24, 47. https://www.fda.gov/downloads/Drugs/Guidances/UCM581965.pdf

Girirajan, S., Campbell, C., & Eichler, E. (2011). 乳鼠心肌提取 HHS Public Access. Physiology & Behavior, 176(5), 139–148. https://doi.org/10.1016/j.bbapap.2017.05.003.Cytochrome

Gu, X., Ke, S., Liu, D., Sheng, T., Thomas, P. E., Rabson, A. B., Gallo, M. A., & Xie, W. (2006). Role of NF- ␬ B in Regulation of PXR-mediated Gene Expression A MECHANISM FOR THE SUPPRESSION OF CYTOCHROME P-450 3A4 BY PROINFLAMMATORY AGENTS *. Journal of Biological Chemistry, 281(26), 17882–17889. https://doi.org/10.1074/jbc.M601302200

Guengerich, F. P. (2021). A history of the roles of cytochrome P450 enzymes in the toxicity of drugs. In Toxicological Research (Vol. 37, Issue 1). Springer. https://doi.org/10.1007/s43188-020-00056-z

Hakkola, J., Hukkanen, J., Turpeinen, M., & Pelkonen, O. (2020). Inhibition and induction of CYP enzymes in humans: an update. In Archives of Toxicology (Vol. 94, Issue 11). Springer Berlin Heidelberg. https://doi.org/10.1007/s00204-020-02936-7

Hodge, C., Marra, F., Marzolini, C., Boyle, A., Gibbons, S., Siccardi, M., Burger, D., Back, D., & Khoo, S. (2020). Drug interactions: A review of the unseen danger of experimental COVID-19 therapies. Journal of Antimicrobial Chemotherapy, 75(12), 3417–3424. https://doi.org/10.1093/jac/dkaa340

In Vitro Drug Interaction Studies-Cytochrome P450 Enzyme-and Transporter-Mediated Drug Interactions Guidance for Industry. (2020). https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm

Kumar, D., & Trivedi, N. (2021). Disease-drug and drug-drug interaction in COVID-19: Risk and assessment. Biomedicine and Pharmacotherapy, 139, 111642. https://doi.org/10.1016/j.biopha.2021.111642

Lamb, D. C., Lei, L., Warrilow, A. G. S., Lepesheva, G. I., Mullins, J. G. L., Waterman, M. R., & Kelly, S. L. (2009). The First Virally Encoded Cytochrome P450. Journal of Virology, 83(16), 8266–8269. https://doi.org/10.1128/jvi.00289-09

Lenoir, C., Terrier, J., Gloor, Y., Curtin, F., Rollason, V., Desmeules, J. A., Daali, Y., Reny, J. L., & Samer, C. F. (2021). Impact of SARS-CoV-2 Infection (COVID-19) on Cytochromes P450 Activity Assessed by the Geneva Cocktail. Clinical Pharmacology and Therapeutics, 110(5), 1358–1367. https://doi.org/10.1002/cpt.2412

Lynch, T., & Price, A. (2007). The Effect of Cytochrome P450 Metabolism on Drug Response, Interactions, and Adverse Effects. www.aafp.org/afp.

Manuscript, A. (2012). Pharmacogenomics : The genetics of variable drug responses. 123(15), 1661–1670. https://doi.org/10.1161/CIRCULATIONAHA.109.914820.Pharmacogenomics

Morris et al., 2012. (2015). 基因的改变NIH Public Access. Gerontology, 61(6), 515–525. https://doi.org/10.1038/clpt.2008.302.Impact

Nebert, D. W., Wikvall, K., & Miller, W. L. (2013). Human cytochromes P450 in health and disease. In Philosophical Transactions of the Royal Society B: Biological Sciences (Vol. 368, Issue 1612). Royal Society. https://doi.org/10.1098/rstb.2012.0431

Nelson, D. R. (2009). The cytochrome P450 homepage. Human Genomics, 4(1), 59–65. https://doi.org/10.1186/1479-7364-4-1-59

Perlin, D. S., Neil, G. A., Anderson, C., Zafir-Lavie, I., Raines, S., Ware, C. F., & Wilkins, H. J. (2022). Randomized, double-blind, controlled trial of human anti-LIGHT monoclonal antibody in COVID-19 acute respiratory distress syndrome. Journal of Clinical Investigation, 132(3), 0–7. https://doi.org/10.1172/JCI153173

Rodriguez-Morales, A. J., Cardona-Ospina, J. A., Gutiérrez-Ocampo, E., Villamizar-Peña, R., Holguin-Rivera, Y., Escalera-Antezana, J. P., Alvarado-Arnez, L. E., Bonilla-Aldana, D. K., Franco-Paredes, C., Henao-Martinez, A. F., Paniz-Mondolfi, A., Lagos-Grisales, G. J., Ramírez-Vallejo, E., Suárez, J. A., Zambrano, L. I., Villamil-Gómez, W. E., Balbin-Ramon, G. J., Rabaan, A. A., Harapan, H., … Sah, R. (2020). Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. In Travel Medicine and Infectious Disease (Vol. 34). Elsevier USA. https://doi.org/10.1016/j.tmaid.2020.101623

Rubin, R. (2022). Questions Remain about Who Will Get Monoclonal Antibodies for COVID-19 Preexposure Prophylaxis. JAMA - Journal of the American Medical Association, 327(3), 207–208. https://doi.org/10.1001/jama.2021.23557

Smit, C., Peeters, M. Y. M., van den Anker, J. N., & Knibbe, C. A. J. (2020). Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties. Clinical Pharmacokinetics, 59(6), 659–669. https://doi.org/10.1007/s40262-020-00891-1

Stavropoulou, E., Pircalabioru, G. G., & Bezirtzoglou, E. (2018). The role of cytochromes P450 in infection. In Frontiers in Immunology (Vol. 9, Issue JAN). Frontiers Media S.A. https://doi.org/10.3389/fimmu.2018.00089

Stresser, D. M., Crespi, C. L., & Patten, C. (n.d.). Cytochrome P450 Enzyme Mapping in Drug Discovery using Corning ® Supersomes TM Enzymes Application Note 467.

Thompson, T. N. (2009). Safety Testing of Drug Metabolites. Annual Reports in Medicinal Chemistry, 44(1), 459–474. https://doi.org/10.1016/S0065-7743(09)04422-4

Tyzack, J. D. (2019). Computational methods and tools to predict cytochrome P450 metabolism for drug discovery. November 2018, 377–386. https://doi.org/10.1111/cbdd.13445

Veith, H., Southall, N., Huang, R., James, T., Fayne, D., Artemenko, N., Shen, M., Inglese, J., Austin, C. P., Lloyd, D. G., & Auld, D. S. (2009). Comprehensive characterization of cytochrome P450 isozyme selectivity across chemical libraries. Nature Biotechnology, 27(11), 1050–1055. https://doi.org/10.1038/nbt.1581

Verderese, J. P., Stepanova, M., Lam, B., Racila, A., Kolacevski, A., Allen, D., Hodson, E., Aslani-Amoli, B., Homeyer, M., Stanmyre, S., Stevens, H., Garofalo, S., Henry, L., Venkatesan, C., Gerber, L. H., Motew, S. J., Jones, J. S., & Younossi, Z. M. (2022). Neutralizing Monoclonal Antibody Treatment Reduces Hospitalization for Mild and Moderate Coronavirus Disease 2019 (COVID-19): A Real-World Experience. Clinical Infectious Diseases, 74(6), 1063–1069. https://doi.org/10.1093/cid/ciab579

Wang, G., Xiao, B., Deng, J., Gong, L., Li, Y., Li, J., & Zhong, Y. (2022). The Role of Cytochrome P450 Enzymes in COVID-19 Pathogenesis and Therapy. Frontiers in Pharmacology, 13(February), 1–15. https://doi.org/10.3389/fphar.2022.791922

Zahr, N., Urien, S., Llopis, B., Pourcher, V., Paccoud, O., Bleibtreu, A., Mayaux, J., Gandjbakhch, E., Hekimian, G., Combes, A., Benveniste, O., Saadoun, D., Allenbach, Y., Pinna, B., Cacoub, P., Funck-Brentano, C., & Salem, J. E. (2021). Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19. Therapies, 76(4), 285–295. https://doi.org/10.1016/j.therap.2021.01.056

Zanger, U. M., & Schwab, M. (2013a). Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. In Pharmacology and Therapeutics (Vol. 138, Issue 1, pp. 103–141). https://doi.org/10.1016/j.pharmthera.2012.12.007

Zanger, U. M., & Schwab, M. (2013b). Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. In Pharmacology and Therapeutics (Vol. 138, Issue 1, pp. 103–141). https://doi.org/10.1016/j.pharmthera.2012.12.007

Zhao, M., Ma, J., Li, M., Zhang, Y., Jiang, B., Zhao, X., Huai, C., Shen, L., Zhang, N., He, L., & Qin, S. (2021). Cytochrome p450 enzymes and drug metabolism in humans. International Journal of Molecular Sciences, 22(23), 1–16. https://doi.org/10.3390/ijms222312808

Zhou, C., Tabb, M. M., Nelson, E. L., Grün, F., Verma, S., Sadatrafiei, A., Lin, M., Mallick, S., Forman, B. M., Thummel, K. E., & Blumberg, B. (2006). Mutual repression between steroid and xenobiotic receptor and NF- κ B signaling pathways links xenobiotic metabolism and inflammation. 116(8). https://doi.org/10.1172/JCI26283.2280